TB-500 is among the most studied synthetic peptides in the tissue repair research space. Like BPC-157, it has generated substantial community interest and an extensive body of preclinical literature — along with a common pattern of claims that significantly exceed what the current evidence actually establishes.
This guide provides a thorough, evidence-grounded overview of TB-500 for researchers: what it is at a molecular level, what makes it scientifically interesting, what the preclinical literature has examined, where the human data actually stands, and how its regulatory status has evolved through 2026.
This content is for educational and research purposes only. No therapeutic claims are made or implied. TB-500 is not approved for human therapeutic use.
What Is TB-500?
TB-500 is a synthetic peptide based on the active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene. Thymosin Beta-4 is one of the most abundant intracellular peptides in mammalian cells and is found in virtually every tissue.
TB-500 specifically corresponds to a shorter fragment — approximately 17 amino acids — representing the actin-binding domain of the full Thymosin Beta-4 molecule. This is the region considered responsible for the majority of Tβ4’s observed biological activities in preclinical research.
The distinction between TB-500 and full-length Thymosin Beta-4 matters scientifically. They are not the same compound, and data from full-length Tβ4 studies — including those involved in clinical programs — does not automatically transfer to TB-500 as a research compound.
The Molecular Mechanism: Actin Biology
TB-500’s primary and best-characterized molecular function is G-actin sequestration — the binding of monomeric (globular) actin to regulate the equilibrium between G-actin (the monomer pool) and F-actin (filamentous actin).
Why does this matter? Actin dynamics are fundamental to cell behavior. The balance between G-actin and F-actin governs:
- Cell migration — Cells use actin filament polymerization to generate the mechanical forces that drive movement. TB-500’s regulation of this equilibrium influences how cells migrate into sites of injury or inflammation.
- Angiogenesis — The formation of new blood vessels depends on endothelial cell migration, which is actin-dependent. Preclinical research has examined whether TB-500 influences angiogenic processes through this mechanism.
- Inflammatory signaling — Actin dynamics intersect with several inflammatory signaling pathways, and Thymosin Beta-4 has been studied in anti-inflammatory contexts in preclinical models.
- Progenitor cell recruitment — Some research has examined whether Tβ4/TB-500 influences the mobilization and homing of stem and progenitor cells to sites of tissue injury.
This mechanistic grounding in fundamental cell biology is part of what makes TB-500 an attractive subject for tissue repair research — the proposed mechanisms are biologically plausible and connected to well-characterized cellular processes.
What Preclinical Studies Have Examined
The preclinical literature on Thymosin Beta-4 and its analogs spans multiple tissue systems and is considerably broader than the TB-500 fragment specifically. Researchers should be careful to distinguish studies of full-length Tβ4 from studies of the shorter TB-500 fragment.
Wound Healing and Dermal Repair
Early landmark research by Philp et al. published in the Journal of Investigative Dermatology demonstrated that topical and systemic Thymosin Beta-4 accelerated full-thickness dermal wound healing in rodent models, including increased re-epithelialization and keratinocyte migration. This study helped establish the wound healing research framework for Tβ4-related compounds.
Cardiac Research
TB-500 has one of the more developed cardiac preclinical evidence bases among research peptides. Studies in rodent cardiac injury models — including models of myocardial infarction — have examined whether Tβ4 administration supports cardiomyocyte survival, promotes angiogenesis in the injured myocardium, and activates cardiac progenitor cells. NIH-funded research interest in this area has produced a reasonably substantial literature, though exclusively in animal models.
Musculoskeletal and Tendon Research
Preclinical work has explored TB-500 and full-length Tβ4 in tendon, ligament, and muscle injury models, examining healing timelines and histological outcomes. This area of research overlaps significantly with the BPC-157 preclinical literature.
Neurological Research
Studies in rodent traumatic brain injury models have examined Thymosin Beta-4 in relation to neuronal survival, neuroinflammation reduction, and angiogenesis in the injury zone. Results in these animal models have been of research interest, though human translation remains entirely unestablished.
Ophthalmic Research
Full-length Thymosin Beta-4 has been developed as an ophthalmic therapeutic (RGN-259) and has reached Phase 3 clinical trials for dry eye disease. This represents the furthest clinical development of any Tβ4-based compound, though it involves the full peptide rather than the TB-500 fragment and has not resulted in FDA approval as of April 2026.
Where Human Data Stands for TB-500
The human data situation for TB-500 (the 17-amino acid fragment specifically) is unambiguous: as of April 2026, no completed human efficacy trials for TB-500 have been published. There is no published human pharmacokinetic data for the fragment. Clinical data from full-length Tβ4 programs does not directly transfer to TB-500.
The preclinical evidence is meaningful and scientifically grounded. The human evidence for TB-500 specifically does not yet exist. Researchers should approach claims about human outcomes from TB-500 with appropriate epistemic humility — they are extrapolations from animal models, not established clinical findings.
TB-500 Regulatory Status in 2026
TB-500 was included in the FDA’s Category 2 restricted compounding list in late 2023, prohibiting licensed compounding pharmacies from preparing it for patient use. Following the February 2026 HHS announcement and the April 23, 2026, procedural removal from Category 2, TB-500 is among the seven peptides — alongside BPC-157, KPV, MOTs-C, Emideltide, Semax, and Epitalon — that the FDA’s Pharmacy Compounding Advisory Committee is scheduled to review on July 23–24, 2026, to determine eligibility for the 503A bulks list.
As with BPC-157, the April 2026 removal from Category 2 does not automatically authorize compounding. The PCAC review and subsequent FDA action will determine the formal pathway.
As a research compound sold under a research use only designation, TB-500’s availability from research suppliers is governed by a separate framework from the compounding pharmacy rules.
Sourcing and Quality Considerations for TB-500 Research
TB-500 is a larger peptide (17 amino acids) than many commonly studied compounds, which introduces specific quality considerations.
Mass Spectrometry Interpretation
Larger peptides like TB-500 commonly appear in mass spectrometry data as multiply charged ions — for example, [M+2H]²⁺, which appears at half the actual molecular weight. Researchers reviewing COAs for TB-500 should confirm their supplier’s COA specifies which ion form is being reported, to avoid misreading the mass data.
Storage Requirements
TB-500 in lyophilized form should be stored at -20°C or colder. Reconstituted solutions have limited stability and should be used within the timeframe specified on the product COA.
Third-Party Testing
As with all research peptides, verify that the COA for your TB-500 comes from a named, accredited third-party laboratory and includes both HPLC purity and mass spectrometry identity confirmation.